Gregory P Sargen's most recent trade in Protara Therapeutics Inc was a trade of 24,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Protara Therapeutics Inc | Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Avid Bioservices Inc | Gregory P. Sargen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 26,756 | 36,368 (0%) | 0% | - | Common Stock, $0.001 par value | |
| Avid Bioservices Inc | Gregory P. Sargen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 26,756 | 0 | - | - | Restricted Stock Units | |
| Avid Bioservices Inc | Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2024 | 8,147 | 8,147 | - | - | Restricted Stock Units | |
| Protara Therapeutics Inc | Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Protara Therapeutics Inc | Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Avid Bioservices Inc | Gregory P. Sargen | Director | Sale of securities on an exchange or to another person at price $ 20.24 per share. | 11 Apr 2023 | 7,011 | 0 (0%) | 0% | 20.2 | 141,919 | Common Stock, $0.001 par value |
| Protara Therapeutics Inc | Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Avid Bioservices Inc | Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 4,632 | 4,632 | - | - | Restricted Stock Units | |
| Avid Bioservices Inc | Gregory P. Sargen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2021 | 2,379 | 0 | - | - | Restricted Stock Units | |
| Avid Bioservices Inc | Gregory P. Sargen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2021 | 2,379 | 2,379 (0%) | 0% | - | Common Stock, $0.001 par balue | |
| Protara Therapeutics Inc | Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Avid Bioservices Inc | Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2020 | 10,030 | 124,305 | - | - | Stock Option (right to buy) | |
| Avid Bioservices Inc | Gregory P. Sargen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2020 | 2,379 | 2,379 | - | - | Restricted Stock Units |